254 related articles for article (PubMed ID: 33207010)
1. Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
Castillo JJ; Abeykoon JP; Gustine JN; Zanwar S; Mein K; Flynn CA; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; King R; Yang G; Hunter ZR; Advani RH; Palomba ML; Ansell SM; Gertz MA; Kapoor P; Treon SP
Br J Haematol; 2021 Feb; 192(3):542-550. PubMed ID: 33207010
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
[TBL] [Abstract][Full Text] [Related]
3. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
4. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Castillo JJ; Meid K; Gustine JN; Leventoff C; White T; Flynn CA; Sarosiek S; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Branagan AR; O'Donnell E; Raje N; Yee AJ; Patterson CJ; Hunter ZR; Treon SP
Leukemia; 2022 Feb; 36(2):532-539. PubMed ID: 34531537
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
Treon SP; Meid K; Gustine J; Yang G; Xu L; Liu X; Patterson CJ; Hunter ZR; Branagan AR; Laubach JP; Ghobrial IM; Palomba ML; Advani R; Castillo JJ
J Clin Oncol; 2021 Feb; 39(6):565-575. PubMed ID: 32931398
[TBL] [Abstract][Full Text] [Related]
7. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract][Full Text] [Related]
8. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
Castillo JJ; Sarosiek SR; Gustine JN; Flynn CA; Leventoff CR; White TP; Meid K; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Hunter ZR; Patterson CJ; Branagan AR; Treon SP
Blood Adv; 2022 Feb; 6(3):1015-1024. PubMed ID: 34965304
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.
Lim KJC; Tam CS
Expert Opin Pharmacother; 2020 Sep; 21(13):1555-1564. PubMed ID: 32603202
[TBL] [Abstract][Full Text] [Related]
10. Partial responses to ibrutinib in Waldenström macroglobulinaemia - good enough?
Vitolo U; Novo M; Santambrogio E
Br J Haematol; 2021 Feb; 192(3):423-424. PubMed ID: 33206997
[No Abstract] [Full Text] [Related]
11. The role of ibrutinib in COVID-19 hyperinflammation: A case report.
Maynard S; Ros-Soto J; Chaidos A; Innes A; Paleja K; Mirvis E; Buti N; Sharp H; Palanicawandar R; Milojkovic D
Int J Infect Dis; 2021 Apr; 105():274-276. PubMed ID: 33607304
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
Parrondo RD; Dutta N; LaPlant BR; Elliott J; Fernandez A; Zimmerman A; Cicco G; Han B; Heslop K; Chapin D; Sher T; Roy V; Rasheed A; Das S; Chanan-Khan AA; Paulus A; Ailawadhi S
Br J Haematol; 2024 May; 204(5):1825-1829. PubMed ID: 38286472
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
[TBL] [Abstract][Full Text] [Related]
14. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate
Trotman J; Buske C; Tedeschi A; Matous JV; MacDonald D; Tam CS; Tournilhac O; Ma S; Treon SP; Oriol A; Ping J; Briso EM; Arango-Hisijara I; Dimopoulos MA
Clin Cancer Res; 2021 Nov; 27(21):5793-5800. PubMed ID: 34380643
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
Treon SP; Meid K; Hunter ZR; Flynn CA; Sarosiek SR; Leventoff CR; White TP; Cao Y; Roccaro AM; Sacco A; Demos MG; Guerrera ML; Kofides A; Liu X; Xu L; Patterson CJ; Munshi M; Tsakmaklis N; Yang G; Ghobrial IM; Branagan AR; Castillo JJ
Blood; 2021 Oct; 138(17):1535-1539. PubMed ID: 34289017
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Castillo JJ; Xu L; Gustine JN; Keezer A; Meid K; Dubeau TE; Liu X; Demos MG; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Yang G; Hunter ZR; Treon SP
Br J Haematol; 2019 Nov; 187(3):356-363. PubMed ID: 31267520
[TBL] [Abstract][Full Text] [Related]
17. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Castillo JJ; LaMacchia J; Flynn CA; Sarosiek S; Pozdnyakova O; Treon SP
Br J Haematol; 2021 Nov; 195(3):466-468. PubMed ID: 34355802
[No Abstract] [Full Text] [Related]
18. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.
Yi S; Cai Z; Hu Y; He A; Gao S; Li Q; Sha L; Zhang N; Ren Y; Gai X; Yang X; Qin R; Qiu L
Adv Ther; 2024 Feb; 41(2):672-685. PubMed ID: 38079089
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
Castillo JJ; Branagan AR; Sermer D; Flynn CA; Meid K; Little M; Stockman K; White T; Canning A; Guerrera ML; Kofides A; Liu S; Liu X; Richardson K; Tsakmaklis N; Patterson CJ; Hunter ZR; Treon SP; Sarosiek S
Blood; 2024 Feb; 143(7):582-591. PubMed ID: 37971194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]